Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma

類似資料

• Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
  著者:: Kudo, Masatoshi
  出版事項: (2018)
• A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma
  著者:: Kudo, Masatoshi
  出版事項: (2020)
• A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
  著者:: Kudo, Masatoshi
  出版事項: (2017)
• Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure
  著者:: Maida, Marcello, 等
  出版事項: (2015)
• Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
  著者:: Trojan, Jörg, 等
  出版事項: (2016)